Gilead Sciences, Inc. 13D and 13G filings for Xilio Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-12 4:39 pm Purchase | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 1,036,977 19.900% | 278,838 (+36.78%) | Filing |
| 2025-08-14 4:42 pm Purchase | 2025-06-30 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 758,139 19.900% | 107,750 (+16.57%) | Filing |
| 2024-12-19 4:15 pm Purchase | 2024-12-18 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 650,389 19.900% | 125,712 (+23.96%) | Filing |
| 2024-04-05 4:31 pm Purchase | 2024-03-27 | 13G | XILIO THERAPEUTICS INC XLO | GILEAD SCIENCES INC. GILD | 524,677 19.900% | 524,677 (New Position) | Filing |